BioCentury | Sep 11, 2019
Product Development

Pharmas’ challenge: learning from rare disease units while leaving them alone

How do you build a rare disease portfolio inside a pharma focused on large indications, and do right by both the new and the old? That’s a question faced by pharmas expanding from their traditional...
BioCentury | Oct 26, 2018
Company News

Canbridge, WuXi team up to develop rare disease therapies in China

...Canbridge Life Sciences Ltd. (Beijing, China) and WuXi Biologics Inc. (HKSE:2269) partnered to develop rare disease therapeutics in...
BioCentury | Oct 23, 2018
Company News

Canbridge, WuXi team up to develop rare disease therapies in China

...Canbridge Life Sciences Ltd. (Beijing, China) and WuXi Biologics Inc. (HKSE:2269) partnered to develop rare disease therapeutics in...
BioCentury | Mar 23, 2018
Financial News

Beacon launches biotech incubator

...Capital said its focus is on “novel and bioequivalent IP” in oncology, neurodegenerative disease and rare disease therapeutics...
BioCentury | Mar 20, 2018
Financial News

Beacon launches NY/NJ biotech incubator

...Capital said its focus is on “novel and bioequivalent IP” in oncology, neurodegenerative disease and rare disease therapeutics. Meghan...
BioCentury | Feb 13, 2018
Politics & Policy

FDA to hold rare disease workshop

...will hold a one-day public workshop on March 19 to solicit feedback on issues facing rare disease therapeutics...
BioCentury | Oct 12, 2017
Finance

IRDiRC dreams bigger

...IRDiRC's guidelines and policies on a series of topics impacting research and development. Data on rare disease therapeutics...
BioCentury | Aug 11, 2017
Company News

Alexion partners with GNS, Sema4

...Forward Simulation (REFS) platform from GNS Healthcare Inc. (Cambridge, Mass.) to accelerate development of new rare disease therapeutics...
BioCentury | Aug 10, 2017
Company News

Alexion rebuilding pipeline with big data deals

...Forward Simulation (REFS) platform from GNS Healthcare Inc. (Cambridge, Mass.) to accelerate development of new rare disease therapeutics...
BioCentury | Jan 6, 2014
Company News

Swedish Orphan Biovitrum, Syngenta, Rare Disease Therapeutics sales and marketing update

...On Dec. 20, 2013, Swedish Orphan said it terminated a distribution deal with Rare Disease Therapeutics for Orfadin...
...Orphan indications. Swedish Orphan Biovitrum AB (SSE:SOBI), Stockholm, Sweden Syngenta AG (SIX:SYNN; NYSE:SYT), Basel, Switzerland Rare Disease Therapeutics Inc....
Items per page:
1 - 10 of 16
BioCentury | Sep 11, 2019
Product Development

Pharmas’ challenge: learning from rare disease units while leaving them alone

How do you build a rare disease portfolio inside a pharma focused on large indications, and do right by both the new and the old? That’s a question faced by pharmas expanding from their traditional...
BioCentury | Oct 26, 2018
Company News

Canbridge, WuXi team up to develop rare disease therapies in China

...Canbridge Life Sciences Ltd. (Beijing, China) and WuXi Biologics Inc. (HKSE:2269) partnered to develop rare disease therapeutics in...
BioCentury | Oct 23, 2018
Company News

Canbridge, WuXi team up to develop rare disease therapies in China

...Canbridge Life Sciences Ltd. (Beijing, China) and WuXi Biologics Inc. (HKSE:2269) partnered to develop rare disease therapeutics in...
BioCentury | Mar 23, 2018
Financial News

Beacon launches biotech incubator

...Capital said its focus is on “novel and bioequivalent IP” in oncology, neurodegenerative disease and rare disease therapeutics...
BioCentury | Mar 20, 2018
Financial News

Beacon launches NY/NJ biotech incubator

...Capital said its focus is on “novel and bioequivalent IP” in oncology, neurodegenerative disease and rare disease therapeutics. Meghan...
BioCentury | Feb 13, 2018
Politics & Policy

FDA to hold rare disease workshop

...will hold a one-day public workshop on March 19 to solicit feedback on issues facing rare disease therapeutics...
BioCentury | Oct 12, 2017
Finance

IRDiRC dreams bigger

...IRDiRC's guidelines and policies on a series of topics impacting research and development. Data on rare disease therapeutics...
BioCentury | Aug 11, 2017
Company News

Alexion partners with GNS, Sema4

...Forward Simulation (REFS) platform from GNS Healthcare Inc. (Cambridge, Mass.) to accelerate development of new rare disease therapeutics...
BioCentury | Aug 10, 2017
Company News

Alexion rebuilding pipeline with big data deals

...Forward Simulation (REFS) platform from GNS Healthcare Inc. (Cambridge, Mass.) to accelerate development of new rare disease therapeutics...
BioCentury | Jan 6, 2014
Company News

Swedish Orphan Biovitrum, Syngenta, Rare Disease Therapeutics sales and marketing update

...On Dec. 20, 2013, Swedish Orphan said it terminated a distribution deal with Rare Disease Therapeutics for Orfadin...
...Orphan indications. Swedish Orphan Biovitrum AB (SSE:SOBI), Stockholm, Sweden Syngenta AG (SIX:SYNN; NYSE:SYT), Basel, Switzerland Rare Disease Therapeutics Inc....
Items per page:
1 - 10 of 16